PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Canada Drug Forecast and Market Analysis to 2022

Description:

PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Canada Drug Forecast and Market Analysis to 2022

Summary

Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV-related liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. GlobalData expects that the growing popularity of pediatric combination vaccines, along with the arrival of vaccines that achieve higher seroconversion rates in high-risk adults, will serve to stimulate growth in the marketplace over the forecast period. Country-specific immunization recommendations and policy implementation will be an essential metric for determining future vaccine uptake in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) and Canada.

In 2012, the Canadian HBV vaccine market was estimated to be worth almost $18m, with the majority of vaccine sales occurring within the routine childhood immunization program. Twinrix has enjoyed success largely due to its use in school-based immunization programs in Quebec and other Canadian provinces that universally vaccinate preteens instead of infants. The adult vaccine market in Canada represented a small percentage of total sales in 2012.

Scope

- Overview of Hepatitis B disease including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Canada including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Canada from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the Canada Hepatitis B disease market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Hepatitis B disease
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in Canada

Contents:

1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Overview
3.2 Etiology and Pathophysiology
3.2.1 Etiology
9.4.8 Individual Vaccine Assumptions
9.4.9 Pricing of Pipeline Vaccines
9.5 Physicians and Specialists Included in this Study
9.5.1 Interviews of Key Opinion Leaders (KOLs)
9.5.2 Online Survey of High-Prescribing Physicians (non-KOLs)
9.6 About the Authors
9.6.1 Analyst
9.6.2 Therapy Area Director
9.6.3 Global Head of Healthcare
9.7 About Us
9.8 Disclaimer

1.1 List of Tables
Table 1: Modes of HBV Transmission
Table 2: HBV Serological Markers and Test Interpretations
Table 3: Symptoms of HBV Infection
Table 4: HBV Vaccination Advisory Committees by Country
Table 5: HBV Immunization Recommendations by Country
Table 6: Targeted Age Group(s) for Routine Immunization and Most Administered HBV Vaccines by Country in the Global Markets, 2014
Table 7: Targeted Age Group(s) for Routine HBV Immunization in Canada, by Province or Territory, 2014
Table 8: Leading Vaccines for HBV, 2014
Table 9: Product Profile - Engerix-B
Table 10: Immunogenicity Profile - Engerix-B
Table 11: Safety Profile - Engerix-B
Table 12: Engerix-B SWOT Analysis, 2014
Table 13: Product Profile - Recombivax HB
Table 14: Immunogenicity Profile - Recombivax HB
Table 15: Safety Profile - Recombivax HB
Table 16: Recombivax HB SWOT Analysis, 2014
Table 17: Product Profile - Infanrix Hexa
Table 18: Immunogenicity Profile - Infanrix Hexa
Table 19: Safety Profile - Infanrix Hexa
Table 20: Infanrix Hexa SWOT Analysis, 2014
Table 21: Product Profile - Hexyon
Table 22: Immunogenicity Profile - Hexyon
Table 23: Safety Profile - Hexyon
Table 24: Hexyon SWOT Analysis, 2014
Table 25: Product Profile - Twinrix
Table 26: Immunogenicity Profile - Twinrix
Table 27: Safety Profile - Twinrix
Table 28: Twinrix SWOT Analysis, 2014
Table 29: Unmet Need and Opportunity in Prophylactic HBV Vaccines
Table 30: HBV Vaccines - Phase Pipeline, 2014
Table 31: Comparison of Vaccines in Development for HBV, 2014
Table 32: Product Profile - Heplisav
Table 33: Immunogenicity Profile - Heplisav
Table 34: Safety Profile - Heplisav
Table 35: Heplisav SWOT Analysis, 2014
Table 36: Sales Forecasts ($) for HBV Vaccines in Canada, 2012-2022
Table 37: Key Events Impacting Sales for HBV Vaccines in Canada, 2014
Table 38: Canada HBV Vaccine Market - Drivers and Barriers, 2014
Table 39: Patient Population(s) Targeted for HBV Vaccination in the Pediatric Market, Canada
Table 40: Patient Population(s) Targeted for HBV Vaccination in the Adult Market, Canada
Table 41: Key Launch Dates
Table 42: High-Prescribing Physicians (non-KOLs) Surveyed, Canada

1.2 List of Figures
Figure 1: HBV Structure and the Recombinant Vaccine Development Process
Figure 2: High-Prescriber Estimation of Pediatric HBV Vaccine Patient Share in Canada, 2014
Figure 3: Competitive Assessment of Late-Stage Pipeline Agents and Marketed Products in HBV Vaccines, 2012-2022
Figure 4: Sales for HBV Vaccines in Canada, 2012-2022
Ordering: Order Online - http://www.researchandmarkets.com/reports/2785108/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit

http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Canada Drug Forecast and Market Analysis to 2022
Web Address: http://www.researchandmarkets.com/reports/2785108/
Office Code: SC6I5RX7

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>✔️</td>
<td>USD 4995</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 9990</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>✔️</td>
<td>USD 14985</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ______________________ Last Name: ______________________
Email Address: * ______________________
Job Title: ______________________
Organisation: ______________________
Address: ______________________
City: ______________________
Postal / Zip Code: ______________________
Country: ______________________
Phone Number: ______________________
Fax Number: ______________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card:  
You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check:  
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer:  
Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: __________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World